# Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389

> **NCT04322032** · PHASE1 · UNKNOWN · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 34 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Reference drug
- **DRUG:** Test drug

## Key facts

- **NCT ID:** NCT04322032
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-06
- **Primary completion:** 2020-05-12
- **Final completion:** 2020-05-18
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2020-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322032, "Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-389". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04322032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*